{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T18:50:09Z","timestamp":1790880609515,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Clinical Trials Network","award":["CA180888"],"award-info":[{"award-number":["CA180888"]}]},{"name":"National Clinical Trials Network","award":["CA180819"],"award-info":[{"award-number":["CA180819"]}]},{"name":"National Clinical Trials Network","award":["CA180846"],"award-info":[{"award-number":["CA180846"]}]},{"name":"NCI Community Oncology Research Program","award":["CA189953"],"award-info":[{"award-number":["CA189953"]}]},{"name":"NCI Community Oncology Research Program","award":["CA189808"],"award-info":[{"award-number":["CA189808"]}]},{"name":"NCI Community Oncology Research Program","award":["CA189957"],"award-info":[{"award-number":["CA189957"]}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health (NIH)","doi-asserted-by":"publisher","award":["U10HL069294"],"award-info":[{"award-number":["U10HL069294"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NIH\/NCI","award":["CA46368"],"award-info":[{"award-number":["CA46368"]}]},{"name":"NIH\/NCI","award":["CA46282"],"award-info":[{"award-number":["CA46282"]}]},{"name":"NIH\/NCI","award":["CA76132"],"award-info":[{"award-number":["CA76132"]}]}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.bbmt.2017.12.798","type":"journal-article","created":{"date-parts":[[2017,12,28]],"date-time":"2017-12-28T13:01:43Z","timestamp":1514466103000},"page":"700-707","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Tandem Autologous Hematopoietic Cell Transplantation for Patients with Primary Progressive or Recurrent Hodgkin Lymphoma: A SWOG and Blood and Marrow Transplant Clinical Trials Network Phase II Trial (SWOG S0410\/BMT CTN 0703)"],"prefix":"10.1016","volume":"24","author":[{"given":"Eileen P.","family":"Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongli","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan W.","family":"Friedberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis S.","family":"Constine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa M.","family":"Rimsza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0456-8085","authenticated-orcid":false,"given":"James R.","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ginna G.","family":"Laport","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie L.","family":"Popplewell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leona A.","family":"Holmberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonali M.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"LeBlanc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Forman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard I.","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick J.","family":"Stiff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2017.12.798_bib0010","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/0140-6736(93)92411-L","article-title":"Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial","volume":"341","author":"Linch","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.bbmt.2017.12.798_bib0015","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","article-title":"Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial","volume":"359","author":"Schmitz","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.bbmt.2017.12.798_bib0020","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1182\/blood.V85.5.1381.bloodjournal8551381","volume":"85","author":"Nademanee","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.12.798_bib0025","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1182\/blood.V83.5.1193.1193","article-title":"Intensive therapy with cyclophosphamide, carmustine, etoposide +\/\u2212 cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy","volume":"83","author":"Reece","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.12.798_bib0030","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1182\/blood.V89.3.801","article-title":"High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: analysis of the Stanford University results and prognostic indices","volume":"89","author":"Horning","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.12.798_bib0035","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.bbmt.2006.06.006","article-title":"Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma","volume":"12","author":"Majhail","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.12.798_bib0040","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/sj.bmt.1700838","article-title":"Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin's disease: analysis of 280 patients from the French registry. Societe Francaise de Greffe de Moelle","volume":"20","author":"Brice","year":"1997","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.12.798_bib0045","doi-asserted-by":"crossref","first-page":"5980","DOI":"10.1200\/JCO.2007.15.5887","article-title":"Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse\/refractory Hodgkin's lymphoma: results of the prospective multicenter H96 trial by the GELA\/SFGM Study Group","volume":"26","author":"Morschhauser","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2017.12.798_bib0050","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/annonc\/mdi119","article-title":"Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse","volume":"16","author":"Sureda","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bbmt.2017.12.798_bib0055","first-page":"221","article-title":"New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study group","volume":"20","author":"Josting","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2017.12.798_bib0060","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/j.1365-2141.2011.08616.x","article-title":"Autologous stem cell transplant for early relapsed\/refractory Hodgkin lymphoma: results from two transplant centres","volume":"153","author":"Smith","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2017.12.798_bib0065","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1182\/blood.V97.3.616","article-title":"A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model","volume":"97","author":"Moskowitz","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.12.798_bib0070","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S1083-8791(03)00205-2","article-title":"The value of augmented preparative regimens combined with an autologous bone marrow transplant for the management of relapsed or refractory Hodgkin disease: a Southwest Oncology Group phase II trial","volume":"9","author":"Stiff","year":"2003","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.12.798_bib0075","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/sj.bmt.1700682","article-title":"Single and double autotransplants for relapsing\/refractory Hodgkin's disease: results of two consecutive trials","volume":"19","author":"Ahmed","year":"1997","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.12.798_bib0080","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1023\/A:1008343823292","article-title":"Feasibility of tandem autologous stem-cell transplantation (ASCT) in induction failure or very unfavorable (UF) relapse from Hodgkin's disease (HD). SFGM\/GELA Study Group","volume":"10","author":"Brice","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bbmt.2017.12.798_bib0085","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1002\/cncr.11414","volume":"97","author":"Tarella","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.bbmt.2017.12.798_bib0090","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/annonc\/mdi003","article-title":"Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG)","volume":"16","author":"Josting","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bbmt.2017.12.798_bib0095","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.bbmt.2007.01.072","article-title":"Tandem autologous stem cell transplantation for patients with primary refractory or poor risk recurrent Hodgkin lymphoma","volume":"13","author":"Fung","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.12.798_bib0100","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2017.12.798_bib0105","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/bmt.2014.304","article-title":"High-dose melphalan with autologous stem cell support in refractory Hodgkin lymphoma patients as a bridge to second transplant","volume":"50","author":"Castagna","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.12.798_bib0110","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","article-title":"Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"385","author":"Moskowitz","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.bbmt.2017.12.798_bib0115","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1016\/j.bbmt.2014.06.037","article-title":"Brentuximab vedotin is associated with improved progression-free survival after allogeneic transplantation for Hodgkin lymphoma","volume":"20","author":"Chen","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.12.798_bib0120","doi-asserted-by":"crossref","first-page":"703","DOI":"10.3109\/10428194.2014.930852","article-title":"Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma","volume":"56","author":"Illidge","year":"2015","journal-title":"Leuk Lymph"},{"key":"10.1016\/j.bbmt.2017.12.798_bib0125","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1200\/JCO.2007.13.2415","article-title":"Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation","volume":"26","author":"Sureda","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2017.12.798_bib0130","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3324\/haematol.11828","article-title":"Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience","volume":"93","author":"Anderlini","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2017.12.798_bib0135","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00277-010-1146-3","article-title":"Reduced intensity allogeneic hematopoietic cell transplantation can induce durable remission in heavily pretreated relapsed Hodgkin lymphoma","volume":"90","author":"Chen","year":"2011","journal-title":"Ann Hematol"},{"key":"10.1016\/j.bbmt.2017.12.798_bib0140","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.bbmt.2012.10.029","article-title":"Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcome","volume":"19","author":"Nieto","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.12.798_bib0145","doi-asserted-by":"crossref","first-page":"3172","DOI":"10.1182\/blood.V126.23.3172.3172","article-title":"Updated efficacy and safety data from AETHERA trial of consolidation with brentuximab vedotin after autologous stem cell transplant (ASCT) in Hodgkin lymphoma patients at high risk of relapse","volume":"126","author":"Sweetenham","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.12.798_bib0150","doi-asserted-by":"crossref","first-page":"5074","DOI":"10.1200\/JCO.2010.30.5771","article-title":"Dose intensity of chemotherapy in patients with relapsed Hodgkin lymphoma","volume":"28","author":"Josting","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2017.12.798_bib0155","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.bbmt.2015.02.022","article-title":"Role of cytotoxic therapy with hematopoietic cell transplantation in the treatment of Hodgkin lymphoma: guidelines from the American Society for Blood and Marrow Transplantation","volume":"21","author":"Perales","year":"2015","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S108387911731830X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S108387911731830X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:03:15Z","timestamp":1761058995000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S108387911731830X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S108387911731830X"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2017.12.798","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tandem Autologous Hematopoietic Cell Transplantation for Patients with Primary Progressive or Recurrent Hodgkin Lymphoma: A SWOG and Blood and Marrow Transplant Clinical Trials Network Phase II Trial (SWOG S0410\/BMT CTN 0703)","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2017.12.798","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 American Society for Blood and Marrow Transplantation.","name":"copyright","label":"Copyright"}]}}